0
0
10/2/22 at 3:00am
Organization
Mims.com
Author
Roshini Claire Anthony
42 words
0
Comments
Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocat...
You are the first to view
https://specialty.mims.com/topic/brensocatib-has-no-impact-on-covid-19-clinical-outcomes-
Create an account
or login to join the discussion